Gene therapy injection aims to heal diabetic foot sores

NCT ID NCT07391319

Recruiting now Disease control Sponsor: JSC NextGen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial is testing a drug called Neovasculgen, given as injections into the leg muscles, to see if it can help heal foot ulcers in people with diabetes. The study will include 144 adults with type 1 or type 2 diabetes who have a non-healing foot ulcer. Participants will receive either Neovasculgen or a placebo, and researchers will track how many ulcers heal completely within about 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Neovasculgen (a gene therapy drug given as injections into the leg muscles)
What this could lead to: If it works, this could provide a new treatment option to help heal stubborn foot ulcers in people with diabetes, potentially reducing the risk of amputation.
What could go wrong: This is still an early-stage Phase 3 trial with only 144 participants, so results may not apply to everyone. The drug is injected into the muscle and may cause side effects like pain or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELLITUS DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Foot Ulcer type 1 diabetes mellitus type 2 diabetes mellitus ulcer of lower limbs

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELLITUS DIABETES ULCER FOOT

Contacts and locations

Locations

Botkin Hospital
RECRUITING

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.